StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.60−0.75 (-1.46%)

Close on Nov 20, 2026

Genmab A/S Total Contract Liabilities by Year

Total Contract Liabilities (Deferred Collaboration Revenue) ($M)

Genmab A/S Total Contract Liabilities: $119M in FY2025, up 70.0% from a year earlier.

Latest, FY2025
119
Period ended Dec 31, 2025
Change on a year earlier
+70.0%
70 in FY2024
History
3 years
Since FY2023
Sources
1
Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.)

Where the FY2025 figure comes from

“|| Total | 119 | 70 | 76”

Source: Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗

Upfront and milestone payments from AbbVie and Gilead (assumed via Merus) deferred pending satisfaction of R&D performance obligations.

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up total Contract Liabilities

Cite this data

StockData. (2026). Genmab A/S Total Contract Liabilities ($M), annual FY2023–FY2025 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/contract-liabilities-total

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?